Cellid, Co., Ltd. (299660.KQ) KOE
Currency In KRW
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In KRW
Address
Building 142, Korea Seoul National University
Seoul, 08826
Korea (the Republic of)
Phone
82 2 3285 7861
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
64
First IPO Date
February 19, 2019
| Name | Title | Pay | Year Born |
| Yuil Kang Chang | Chief Executive Officer & Representative Director | 0 | N/A |
| Han BeomSoo | Head of R&D Center Construction Task Force & MD | 0 | N/A |
| Kim Yookyung | Head of GMP Center & MD | 0 | N/A |
| SungHo Lee | Head of Management Support Office & Executive Director | 0 | N/A |
Cellid, a South Korean firm established in 2006, specializes in creating immunotherapeutic vaccines designed to combat various cancers and infectious ailments. Their pipeline includes BVAC-C, which targets cervical, head and neck, anal, and genital cancers linked to the human papillomavirus (HPV) antigen. They are also advancing BVAC-B for gastric, ovarian, lung, and pancreatic cancers, focusing on the HER-2/neu antigen, and BVAC-P, intended for prostate, urinary tract, and brain cancers by leveraging PAP/PSMA antigens. Furthermore, Cellid is working on BVAC-M for melanoma and other cancers, utilizing GP100/MAGE-A3 antigens, alongside BVAC-Neo, a personalized immunotherapeutic vaccine solution.